COMMITTED TO ANTI-VIRAL GEL RESEARCH
CarraShield Labs, Inc. has been researching gel formulations for topical use for over 20 years. The result of these efforts is CarraShield®, our formulation technology based on the use of sea algae extracts. The CarraShield technology is so unique it has been granted U.S. Patent 10,688,043 "Personal lubricants comprising lambda-carrageenan." The patent coverage also includes all the European Union, South Korea and Japan.
Research on the ability of the CarraShield technology to help block the transmission of the human papillomavirus (HPV) through skin-to-skin contact has been ongoing since 2006 when the National Cancer Institute published the first paper on in vitro studies they conducted using our formulation.
Most recently the McGill University Medical School human clinical trial on HPV prevention* was published by the McGill research team.
"Study participants using the CarraShield gel personal lubricant had a lower rate of new HPV infections as compared to participants using a placebo."
This is the world's first clinical trial designed to evaluate a topical gel in reducing the risk of genital HPV infections in women.
CONSUMER NOTICE: Study results are for the education of medical and research professionals. The FDA has not reviewed and approved any medical claims. Use Divine 9 only for the pleasure of enjoying an ultra-premium personal lubricant. CarraShield Labs makes no claim that Divine 9 can help prevent, cure or mitigate any disease or infection.
* "Efficacy of a Carrageenan gel Against Transmission of Cervical HPV (CATCH): interim analysis of a randomized, double-blind, placebo-controlled, phase 2B trial" The Journal of Clinical Microbiology and Infection, Feb 2019
The team at CarraShield Labs, has been working with world-class HPV research teams for over 15 years. Intensive research has been surrounding CarraShield®, a safe, natural ingredient from sea algae. The goal of the research is to determine if CarraShield can help block human papillomaviruses (HPV). So far studies have been conducted in laboratory, animal, and human clinical tests.
With the recent U.S. Patent on CarraShield's anti-viral properties now protecting the formula, the research will continue on other uses of the technology.